Application of itaconic acid in the treatment of patients with necrotizing enterocolitis
By using itaconic acid as a drug ingredient, necrotizing enterocolitis in neonatal infants, it improves intestinal injury and reduces the risk of surgery, solving the problem of surgical sequelae in existing treatment methods, and achieving significant improvement of intestinal injury and disease control.
Patent Information
- Application Number
- CN202311148225.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-06
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-09-06
AI Technical Summary
The existing methods for treating necrotizing enterocolitis have serious complications such as short bowel syndrome and intestinal stenosis, and lack effective new therapeutic targets, especially in neonatal patients.
Itaconic acid is used as a pharmaceutical ingredient, and is used to improve intestinal damage to patients with neonatal enterocolitis and alleviate the condition through injection or oral agents (such as granules, tablets, capsules, solutions, and powders). Progress and surgical possibilities.
Itaconic acid significantly improved the intestinal epithelial villus epithelial cell structure of neonatal mice, reduced the degree of intestinal damage, reduced the risk of complications after severe attacks and surgery, and avoided the sequelae of surgical operations such as short bowel syndrome.
Smart Images

Figure CN117462525B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to application of itaconic acid in treating patients with necrotizing enterocolitis. Background Art
[0002] Necrotizing enterocolitis (NEC) is the most common and most serious gastrointestinal emergency in the neonatal stage, which may occur in 10% of extremely low birth weight infants. The mortality rate in these extremely low birth weight infants can be as high as 30%. The current treatment methods for NEC are mainly fasting, gastrointestinal decompression, anti-infection, parenteral nutrition, and surgical treatment. Mild NEC may be similar to feeding intolerance and can be treated conservatively, while severe NEC may rapidly develop intestinal necrosis or intestinal perforation within a few hours, requiring surgical intervention. However, most survivors after surgery have serious complications such as short bowel syndrome or intestinal stenosis, and may even have delayed neurological growth and development. There are many high-risk factors for the onset of NEC, including extremely low birth weight, immature intestinal development, low immunity, dysbiosis, and ischemia and hypoxia, among which premature birth is the most critical. These high-risk factors induce intestinal inflammation and cause NEC, resulting in a series of excessive inflammatory cascade reactions. Therefore, it is particularly important to find new therapeutic targets for NEC.
[0003] Itaconate (ITA) is an endogenous metabolite derived from the mitochondrial tricarboxylic acid (TCA) cycle. It is a mammalian macrophage metabolite. Aconitate decarboxylase in TCA decarboxylates aconitate to produce itaconate. Summary of the invention
[0004] Based on this, the purpose of the present invention is to provide the use of itaconic acid in treating patients with necrotizing enterocolitis. Itaconic acid can effectively improve the intestinal damage of patients with necrotizing enterocolitis.
[0005] To achieve the above purpose, the present invention adopts the following technical solutions.
[0006] Use of itaconic acid in the preparation of a medicament for treating patients with necrotizing enterocolitis.
[0007] In some embodiments, the necrotizing enterocolitis patient is a neonatal necrotizing enterocolitis patient.
[0008] In some embodiments, itaconic acid can improve intestinal tissue damage in patients with necrotizing enterocolitis.
[0009] In some embodiments, the drug is in the form of an injection or an oral agent.
[0010] In some embodiments, the oral dosage form includes granules, tablets, capsules, solutions, and powders.
[0011] The invention also provides a medicine for treating neonatal necrotizing enterocolitis, comprising itaconic acid and pharmaceutically acceptable excipients.
[0012] In some embodiments, the drug is in the form of an injection or an oral agent.
[0013] In some embodiments, the oral dosage form includes granules, tablets, capsules, solutions, and powders.
[0014] The present invention has found through research that itaconic acid can significantly improve the intestinal epithelial villus epithelial cell structure of newborn mice with necrotizing enterocolitis and improve intestinal damage. Therefore, itaconic acid can be used to treat neonatal necrotizing enterocolitis, reduce the possibility of children progressing to severe necrotizing enterocolitis, reduce the possibility of surgery, and avoid surgical sequelae such as short bowel syndrome caused by surgery as much as possible. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 The results of the detection of intestinal villus epithelial cell structure (A) and intestinal histological pathological scores (B) in each group of mice. DETAILED DESCRIPTION
[0016] The experimental methods in the following examples of the present invention without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturers. The various commonly used chemical reagents used in the examples are all commercially available products.
[0017] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0018] The terms "including" and "having" and any variations thereof of the present invention are intended to cover non-exclusive inclusions. For example, a process, method, device, product or equipment comprising a series of steps is not limited to the listed steps or modules, but may optionally include steps not listed, or may optionally include other steps inherent to these processes, methods, products or equipment.
[0019] The following describes the invention in conjunction with specific embodiments.
[0020] Example 1
[0021] This example studies the therapeutic effect of different concentrations of itaconic acid on NEC.
[0022] 1. Experimental Methods
[0023] (1) Establishment of NEC model: The steps for establishing the NEC model of neonatal mice are as follows: 6-8 day old newborn mice were separated from their mothers and kept in an incubator. Formula milk was gavaged at a volume of 30 μl / g / time through the mouth using a clean sterile silicone tube. Fecal microbiota liquid from children with NEC (500 mg / ml) was added to the formula milk. 12.5 ul of fecal microbiota liquid was added per milliliter of formula milk, and gavage was performed 5 times a day. Hypoxia and hypothermia treatment was also given twice a day. The model was established for 4 days.
[0024] (2) Itaconic acid treatment: The mice were divided into control group, NEC group, ITA20mg / kg / d treatment group and ITA40mg / kg / d treatment group. Among them, the newborn mice fed with maternal breast milk were used as the control group; the ITA20mg / kg / d treatment group and the ITA40mg / kg / d treatment group were injected with itaconic acid 20mg / kg / d and 40mg / kg / d, respectively, for 4 days starting from the day before modeling; the NEC group was injected with PBS of the same volume as the treatment group starting from the day before modeling.
[0025] (3) HE staining scores of NEC model mice: 0 points: intact intestinal mucosal villi and normal structure; 1 point: mild edema of villi, epithelial shedding limited to the top of villi; 2 points: damage and necrosis in the middle of villi; 3 points: missing villi, crypts can still be identified; 4 points: complete loss of mucosal epithelial structure, or transmural necrosis. The highest score observed in the sample was determined as the degree of intestinal damage, and a histological score of ≥2 points was confirmed as NEC.
[0026] 2. Experimental results
[0027] like Figure 1 As shown in the figure, compared with the control group, the NEC group had obvious structural damage to the intestinal epithelial villus epithelial cells, and the pathological score increased significantly, confirming that the modeling was successful. The ITA treatment group was able to significantly improve the intestinal epithelial villus epithelial cell structure ( Figure 1 A), reduce the pathological score of NEC ( Figure 1 B).
[0028] The above results indicate that itaconic acid can significantly improve intestinal damage in newborn mice with necrotizing enterocolitis and can be used to treat neonatal necrotizing enterocolitis.
[0029] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0030] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. The use of itaconic acid in the preparation of drugs for treating patients with neonatal necrotizing enterocolitis.
2. The use according to claim 1, It is characterized in that Itaconic acid can improve intestinal tissue damage in patients with necrotizing enterocolitis.
3. The use according to claim 1, It is characterized in that The dosage form of the medicine is injection and oral preparation.
4. The use according to claim 3, It is characterized in that The oral preparations include granules, tablets, capsules, solutions and powders.
Citation Information
Patent Citations
Compounds useful for treating gastrointestinal tract disorders
CN110267944A
Application of dimethyl itaconate in prevention and treatment of ulcerative colitis and canceration of ulcerative colitis
CN110731955A
Compound for inhibiting colitis and application thereof
CN113679733A
Salt form and crystal form of Vanin enzyme inhibitor as well as preparation method and application of salt form and crystal form
CN116768909A
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US20170340623A1
